Moderna's financial history is defined by one of the most dramatic revenue trajectories in the history of public biotechnology — from pre-revenue clinical-stage company to one of the most profitable pharmaceutical businesses globally, followed by a sharp contraction that tests the durability of the mRNA platform's commercial value beyond COVID-19. **The Pre-COVID Financial Foundation** Before the pandemic, Moderna was a pre-revenue company in the traditional pharmaceutical sense — it generated income primarily through government grants, collaboration payments, and milestone fees, not commercial product sales. Total revenue in 2019 was USD 60 million; in 2020, it increased to USD 803 million as BARDA and Operation Warp Speed contracted for COVID-19 vaccine development. The company had accumulated losses of approximately USD 1.5 billion through 2020, funded by the private and public capital it had raised. **The COVID-19 Revenue Peak** The scale of Moderna's COVID-19 vaccine revenue is without parallel in biotechnology history. FY2021 revenue of USD 17.7 billion was generated almost entirely from Spikevax supply agreements — predominantly with the U.S., European, and other governments that had pre-purchased hundreds of millions of doses. FY2022 revenue reached USD 19.3 billion, again dominated by Spikevax. The combined 2021–2022 net income of approximately USD 22 billion transformed Moderna's balance sheet from a heavily funded startup to a cash-rich company with the resources to self-fund an ambitious multi-year pipeline without external capital. This cash accumulation — Moderna held approximately USD 13–15 billion in cash and investments at various points during 2022–2023 — is the financial foundation that makes the post-COVID transition viable. While revenue has contracted sharply, the company has the cash to sustain significant R&D investment, clinical trial costs, and manufacturing infrastructure maintenance through the years required to develop and commercialize next-generation products. **The Revenue Contraction and Cash Management** Moderna's revenue fell to USD 6.8 billion in 2023 and approximately USD 3.2 billion in 2024, reflecting the natural maturation of the COVID-19 vaccine market. Annual booster demand — the sustainable long-term COVID vaccine market — is significantly smaller than the initial mass vaccination market, and Moderna faces competition from Pfizer-BioNTech and from Novavax's protein subunit alternative. The company reported net losses in 2023 and 2024, burning cash at a rate that reflects both the revenue contraction and the sustained R&D investment required to advance the post-COVID pipeline. Moderna has implemented cost reduction measures — workforce reductions of approximately 20% announced in 2024 — aimed at extending its cash runway while maintaining critical pipeline programs. The company's stated goal is to return to profitability by 2026, contingent on the successful commercial launch of multiple pipeline products including its next-generation COVID-RSV combination vaccine, influenza vaccine, and personalized cancer vaccine. **Pipeline Value and Non-Revenue Financial Assets** Moderna's financial value is not fully captured by its current revenue — the company's pipeline represents substantial option value that conventional revenue-based valuation metrics understate. The personalized cancer vaccine program (mRNA-4157/V940), developed in collaboration with Merck, has generated Phase 2b data showing a 49% reduction in recurrence or death in melanoma patients when combined with pembrolizumab (Keytruda) versus pembrolizumab alone. If this result is confirmed in Phase 3 trials and leads to approval, the commercial value of personalized cancer vaccines could be transformative — not just for Moderna's revenue but for oncology treatment paradigms globally.